Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
ATLANTA & GENEVA & ARCHAMPS, FRANCE ? Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today that data from a group of academic collaborators demonstrated that NOX4 is an important driver of kidney injury in diabetes and that its novel, first in class NOX 1 and 4 inhibitor, GKT137831, has the potential to prevent or delay the development of diabetic nephropathy. Data were presented at the American Society of Nephrology?s Kidney Week 2013 in Atlanta and have been accepted for publication in the Journal of the American Society of Nephrology (JASN).
Increased production of reactive oxygen species (ROS) plays a key role in the development of diabetic nephropathy, a major diabetic complication responsible for more than 40 percent of cases of chronic kidney disease. In diabetes, many factors including hyperglycemia drive the expression and activity of NADPH oxidases (NOX enzymes). This in turn activates and/or amplifies pathogenic pathways which lead to kidney injury and progressive fibrosis.
http://www.fortmilltimes.com/2013/11/11/3087020/genkyotex-nox-inhibitor-gkt137831.html
Increased production of reactive oxygen species (ROS) plays a key role in the development of diabetic nephropathy, a major diabetic complication responsible for more than 40 percent of cases of chronic kidney disease. In diabetes, many factors including hyperglycemia drive the expression and activity of NADPH oxidases (NOX enzymes). This in turn activates and/or amplifies pathogenic pathways which lead to kidney injury and progressive fibrosis.
http://www.fortmilltimes.com/2013/11/11/3087020/genkyotex-nox-inhibitor-gkt137831.html